临床试验:在NIT评估的MASH-A多中心随机类安慰剂对照试验 (SAMARA) 中,塞马格卢提德与安慰剂对比
Veeral Ajmera1,2, Raj Vuppalanchi3, Mandana Khalili4,5
1MASLD Research Center, Division of Gastroenterology and Hepatology, University of California at San Diego, La Jolla, CA, USA.
Alimentary pharmacology & therapeutics
|January 13, 2026
概括
非侵入性测试 (NITs) 有效地确定了疑似代谢功能障碍相关的脂肪肝炎 (MASH) 患者的患者,用于治疗血黄. 这种方法在监测治疗反应方面证明了可行性和有效性,显示了关键生物标志物的显著改善.
科学领域:
- 肝病学和胃肠道学
- 药理学和药物开发领域
- 生物标志物和诊断方法
背景情况:
- 代谢功能障碍相关的脂肪肝炎 (MASH) 需要有效的非侵入性测试 (NIT) 来评估患者.
- 塞马格卢提德对MASH治疗具有前景,因此需要验证的符合资格和响应监测方法.
- 目前临床实践指南需要关于MASH管理中NIT实用性的可靠数据.
研究的目的:
- 评估NITs在评估怀疑MASH的患者接受塞马格卢提德治疗的资格方面的实用性.
- 与安慰剂相比,确定NIT在监测治疗对塞马格卢提德的反应方面的有效性.
- 提供随机对照试验 (RCT) 数据,支持基于NIT的MASH管理.
主要方法:
- 一个多中心,随机,双盲,安慰剂控制的52周的试验.
- 患有MASLD和特定标准 (BMI,肝硬度≥8kPa,FAST得分≥0.5) 的患者被随机分配到2.4毫克西马格卢或安慰剂中.
- 主要结局:FAST得分的变化;次要结局:体重的变化,MRI-PDFF,ALT,AST,GT,HbA1c和LDL胆固醇.
主要成果:
- 与安慰剂相比,塞马格卢提德显著降低了FAST得分 (p=0.002).
- 更多的塞马格卢提德接受者实现了≥5%的体重减轻 (64%vs8.3%) 和≥30%的MRI-PDFF减轻 (60%vs17%).
- 塞马格卢提德显著改善了ALT,AST,GT,HbA1c和LDL胆固醇的水平 (p<0.05).
结论:
- 基于NIT的方法是可行的和有效的,用于识别有风险的MASH患者接受西马格卢提德治疗.
- 快得分,ALT,AST和MRI-PDFF是经过验证的NIT,用于监测MASH中semaglutide治疗反应.
- 该RCT提供了关键数据,用于将NIT整合到MASH临床实践指南中.
相关概念视频
01:11Clinical Trials: Overview
4.5K
Clinical development focuses on how the drug will interact with the human body and encompasses four key phases of clinical trials, each serving a specific purpose in assessing the safety and effectiveness of new drugs. These phases overlap and build upon one another. Phase I involves a small group of healthy volunteers (typically 20-80 individuals) or, in cases where significant toxicity is expected, patients with the targeted disease, such as cancer or AIDS. The volunteers are tested for...
4.5K
01:16Clinical Trials
10.1K
Clinical trials are prospective experimental studies conducted on humans to determine the safety and efficacy of treatments, drugs, diet methods, and medical devices. Using statistics in clinical trials enables researchers to derive reasonable and accurate conclusions from the collected data, allowing them to make wise decisions in uncertain situations. In medical research, statistical methods are crucial for preventing errors and bias.
There are four phases in a clinical trial. A phase one...
There are four phases in a clinical trial. A phase one...
10.1K
01:15Bioavailability Study Design: Healthy Subjects Versus Patients
143
Bioavailability studies are essential for evaluating a drug's therapeutic efficacy and understanding its absorption patterns under various physiological conditions. Conducting such studies on target patient populations provides more relevant data by simulating real-world disease states. However, practical challenges often necessitate the use of young, healthy adult volunteers as study subjects.Patients may exhibit altered drug absorption patterns due to the effects of the disease itself,...
143
01:11Bioavailability Study Design: Single Versus Multiple Dose Studies
200
Bioavailability studies are essential for understanding how a drug is absorbed, distributed, metabolized, and excreted in the body. These studies assess the extent and rate at which the active pharmaceutical agent becomes available at the site of action. The design of bioavailability studies can involve single-dose or multiple-dose regimens, each with distinct advantages and limitations.Single-dose studies are the preferred approach due to their simplicity and reduced drug exposure for...
200
01:21Drugs for Treatment of Crohn's Disease in IBD Using Glucocorticoids
425
Glucocorticoids, a class of anti-inflammatory drugs, are pivotal in treating moderate to severe Crohn's disease by inducing remission. They exhibit their anti-inflammatory action by inhibiting the production of inflammatory cytokines such as tumor necrosis factor (TNF)-α, interleukin (IL)-1, and chemokines like IL-8. In addition, they reduce the expression of inflammatory cell adhesion molecules and inhibit gene transcription of nitric oxide synthase, phospholipase A2, cyclooxygenase-2...
425